Abstract:Objective: Choroidal neovascularization (CNV) is a major cause of vision loss in retinal diseases such as age-related macular degeneration (AMD). Previously, we demonstrated that semaphorin3A (Sema3A), which is a chemorepellent guidance molecule, inhibited the formation of retina neovascularization. In the present study, we investigated the anti-angiogenic effects of Sema3A on transforming growth factor beta (TGF-beta) in vitro and in vivo.Methods: Enzyme-linked immunosorbent assays (ELISAs) were used to measure the TGF-beta levels in the vitreous humor of patients with AMD and controls. Human umbilical vein endothelial cells (HUVECs) were used for the in vitro study, and a laser-induced CNV mouse model was prepared for the in vivo study. The HUVECs were incubated with TGF-beta and Sema3A. The proliferation, migration, apoptosis, and tube formation of the cells were then measured using BrdU, Transwell, flow cytometry, and Matrigel assays, respectively, and the SMAD2/3 signaling pathways were analyzed using western blot analysis. The C57BL/6J mouse retina was exposed to a laser to induce choroidal neovascularization (CNV), and Sema3A was injected intravitreously. After 14 days, fundus fluorescein angiography was performed to evaluate the leakage area of the CNV. The vascular endothelial growth factor (VEGF) and TGF-beta concentrations in the retina-choroid complex were measured with ELISA. Components of the p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase-1/2 (ERK1/2), c-Jun NH2-terminal kinase (JNK), and SMAD2/3 signaling pathways in the Sema3A-treated groups were analyzed using western blotting.Results: In this study, we first verified that the vitreous TGF-beta level was higher in patients with neovascular AMD than in the controls. We also showed that Sema3A inhibited TGF-beta-induced HUVEC proliferation, migration, and tube formation and inhibited the downstream SMAD2/3 signaling pathway. Sema3A also induced TGF-beta-stimulated HUVEC apoptosis and inhibited the response of TGF-beta in vitro. In vivo, the TGF-beta level was increased in the CNV mouse model. Sema3A not only inhibited laser-induced CNV formation but also inhibited the uptake of VEGF and TGF-beta. In the western blot analysis, Sema3A was shown to inhibit the phosphorylation of p38 MAPK, ERK1/2, and JNK and to inhibit the SMAD2/3 signaling pathway after Sema3A treatment in CNV mice.Conclusions: Sema3A can be applied as a useful, adjunctive therapeutic strategy for preventing CNV formation.

Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models.

Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis.

Sema3A drastically suppresses tumor growth in oral cancer Xenograft model of mice

SEMA3G-NRP1 Signaling Functions as an Immune Checkpoint that Enables Tumor Immune Evasion by Impairing T Cell Cytotoxicity.

Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells

Targeting Semaphorin 3C in Prostate Cancer With Small Molecules

Inhibition of Pathological Retinal Neovascularization by Semaphorin 3A.

Class-3 semaphorins: Potent multifunctional modulators for angiogenesis-associated diseases

Semaphorin3F down-regulates the expression of integrin α vβ3 and sensitizes multicellular tumor spheroids to chemotherapy via the neuropilin-2 receptor in vitro

Novel Role of Semaphorin 3A in the Growth and Progression of Hepatocellular Carcinoma.

Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and R-Ras.

Semaphorins in tumor microenvironment: Biological mechanisms and therapeutic progress

Semaphorin 6a Regulates Angiogenesis By Modulating Vegf Signaling

Expression of Semaphorin 3c in Breast Cancer and Its Impact on Adhesion and Invasion of Breast Cancer Cells

Ncrnas-Mediated High Expression of SEMA3F Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma

The role of semaphorin 4D as a potential biomarker for antiangiogenic therapy in colorectal cancer

Dependency of Tamoxifen Sensitive and Resistant ER+ Breast Cancer Cells on Semaphorin 3C (SEMA3C) for Growth

Expression of semaphorin 3A (SEMA3A) in breast cancer subtypes

Semaphorin 3A Blocks the Formation of Pathologic Choroidal Neovascularization Induced by Transforming Growth Factor Beta.

Semaphorin 3A Inhibits Tumor Progression Via the Downregulation of Lin28B in Ovarian Cancer

Semaphorin 3F (SEMA3F) influences patient survival in esophageal adenocarcinoma